GI-5005

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
GI-5005
Accession Number
DB05942
Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Recombinant
Description

GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

Synonyms
Not Available
External IDs
GI 5005 / GI-5005
Categories
UNII
Not Available
CAS number
1001913-27-4

Pharmacology

Indication

Investigated for use/treatment in hepatitis (viral, C).

Pharmacodynamics
Not Available
Mechanism of action

The mechanism of action for GI-5005 (i.e. immune elimination of infected hepatic cells) may work synergistically in combination with the current or emerging standard of care, which directly inhibits viral replication, to more effectively eradicate hepatitis C virus from the liver. Additionally, this mechanism of action may offer an option for interferon-intolerant or interferon-contraindicated patients as a long term monotherapy.

GI-5005 is designed to elicit a cellular immune response against cells infected with the HCV virus. The yeast vector is designed not only to stimulate an innate immune response mediated by Toll-like receptors (TLRs), but also to deliver target protein directly to antigen presenting cells, eliciting an antigen-specific helper T cell (CD4) and killer T cells (CD8) cellular immune response to eliminate diseased cells.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of GI-5005 can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of GI-5005 can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of GI-5005 can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of GI-5005 can be decreased when used in combination with Abetimus.
ActeosideThe therapeutic efficacy of GI-5005 can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of GI-5005 can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of GI-5005 can be decreased when used in combination with Afelimomab.
AldesleukinThe therapeutic efficacy of GI-5005 can be decreased when used in combination with Aldesleukin.
AldosteroneThe therapeutic efficacy of GI-5005 can be decreased when used in combination with Aldosterone.
AlefaceptThe therapeutic efficacy of GI-5005 can be decreased when used in combination with Alefacept.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, Bellgrau D, Rodell TC, Apelian D, Franzusoff A, Duke RC: Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007 Feb 9;25(8):1452-63. Epub 2006 Nov 10. [PubMed:17098335]
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHepatitis C Viral Infection1
2CompletedTreatmentGenotype 1 Chronic Hepatitis C1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:28 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates